| INTRODUCTION
Charcot-Marie-Tooth (CMT) disease is a genetically and clinically heterogeneous group of inherited peripheral neuropathies causing progressive degeneration of peripheral motor and sensory neurons. has 23 exons, and exon 1 is non-coding. To date, all mutations observed in CMT-FSGS cluster in exons 2 to 4 in the N-terminus part of the protein, and affect amino acids between positions 57 to 184. 1, 3 All are missense point mutations or, more rarely, short in-frame deletions. Here, we report a three-generation family with a new cryptic splicing mutation in the INF2 gene causing autosomal dominant intermediate CMT with no clinically relevant glomerular dysfunction. In addition, this is the first time an INF2 cryptic splicing mutation is reported.
| PATIENTS AND METHODS

| Standard protocol approvals, registration, and patient consents
This study was approved and performed under the ethical guidelines issued by our institutions for clinical studies and was in compliance with the Helsinki Declaration. The diagnostic procedures were conducted according to the ethics committee of Bicêtre University Hospital, and informed written consent was obtained from all patients.
| Patients
We studied a population of four patients (three males, one female)
with an autosomal dominant CMT disease from a single pedigree originating from Alsace (France).
| Electrophysiological studies
Electrodiagnostic studies included upper and lower limbs nerve conduction studies (NCS) and electromyography (EMG) using a concentric needle electrode in at least three muscles. Electrophysiological studies were performed using conventional equipment and standard methods, and skin temperature was maintained in the range of 32 -34 C.
| Paraclinical investigations
Plasma albumin and plasma creatinine were investigated in all patients, and urine protein was investigated in three cases. Brain and spinal cord magnetic resonance imaging (MRI) was performed in three patients. 2.7 | Minigene constructs for in vitro splicing assay
| Genetic analysis
Minigene constructions for splicing studies were designed as previously described, using (CTAAACAGCCACATATGTTGCTGAAATTCG GTCAGGG) and (CCCCCCTCGACCATATGGTGACCTGGAAGCCTCA GAC) primers. 12 The analyzed sequence included the end of intron were not observed.
| Electrophysiological studies
Electrophysiological examination showed altered lower limb com- 
| In silico predictions for splicing sites
In silico predictions for a splicing site are detailed in the Supporting Information 
| DISCUSSION
In our study, we report a three-generation family with a new cryptic splicing mutation in the INF2 gene causing autosomal dominant intermediate CMT with no clinically relevant glomerular dysfunction.
INF2 gene heterozygous mutations provoke FSGS and CMT-FSGS. 13 Some INF2 mutations appear specific for FSGS or for CMT-FSGS, but others may result in either disease, depending on the individual. 13 To date, INF2 mutations are the only known genetic cause of CMT-FSGS, and patients may also present with cognitive impairment, deafness, and hand deformities. 13 CMT symptoms often appear before FSGS symptoms, and it has been suggested that CMT In this group of four patients, mean CMT evaluation score (CMTES) was 5.7 (5-6).
a Abnormal values.
patients should be screened for proteinuria and, potentially, genotyped for INF2, as a guide for appropriate treatment. 3, 13 In accordance with previous reports, all four patients from our family presented with early-onset and slowly-progressive CMT. However, in contrast with previous reports, our patients presented with minimal or absent glomerular involvement (Table 1) . Indeed, plasma albumin and creatinine were normal in all four cases, and urine protein was normal in one case and mildly raised in three patients (mean: 0.32 g/L [0.18-0.44], N < 0.14). Our patients had a mean age of 51 years (26-87), and we found no correlation between age and glomerular function (Table 1) .
Most interestingly, our family included an 87-year old patient with a 70-year long CMT story, normal plasma albumin and creatinine, and mildly raised urine protein (0.35 g/L, N < 0.14). To note, obstructive sleep apnea (OSA) was observed in two cases and was not linked with overweight (Table 1) . This observation suggests OSA was linked with the disease, as it has been observed in other CMT subtypes such as TRPV4-linked CMT. 14 (Table S1 ).
Unfortunately, predictions were ambiguous and consistent with either a donor or an acceptor site, with only a slight preference for a donor site (Table S1) INF2 belongs to the group of formin proteins regulating nucleation and elongation of actin filaments. 13 Unlike other formins, INF2
can accelerate depolymerization of actin filaments. 13 When mutated, INF2 dysregulates actin-dependent processes, ultimately interfering with myelination and mitochondrial dynamics. 13 Overexpressed FSGS-associated mutants result in altered distribution of INF2 and actin filaments in cultured podocytes, causing damage to the glomerular filtration barrier. 13 Mutations causing CMT-FSGS disturb the subcellular localization of INF2, MAL (myelin and lymphocyte protein), and CDC42 (cell division cycle 42 GTP binding protein), resulting in a defective INF2-MAL-CDC42 pathway causing abnormal actinrequiring vesicular transport. 13 It is speculated that INF2 mutations most likely result in a dominant-negative effect provoking a loss of INF2 auto-inhibition and a major increase in actin polymerization in Schwann cells. 1, 4, 13, 15 Further studies are needed to elucidate the pathogenic mechanisms participating in INF2-related disorders and identify the modifying factors that cause such striking phenotypic variation.
To summarize, this report expands the genetic spectrum of INF2-associated disorders and shows that INF2 mutations may provoke isolated CMT with no clinically relevant kidney involvement. This study also shows that in vitro splicing analysis is a relevant diagnosis tool to investigate potential cryptic splice sites in CMT genes.
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